

Special Issue

The Role of Metabolites in Translational and Clinical Pharmacology

Message from the Guest Editors

This Special Issue aims to provide a comprehensive overview of the importance of drug metabolites in drug discovery and development within translational and clinical pharmacology domains. We invite original research articles, reviews, and short communications related to the field of metabolites. Topics of interest include, but are not limited to, the following areas:

- Absorption, distribution, metabolism, and excretion (ADME) or PK studies of drug metabolites.
- In vitro or in vivo evaluation of drug metabolites as substrates or perpetrators (inhibitors or inducers) of DMET proteins.
- Prediction of PK of drug metabolites in healthy or special populations using physiologically based pharmacokinetic (PBPK) models.
- Prediction of the DDI potential of drug metabolites using basic, static mechanistic, or dynamic PBPK models.
- Endogenous biomarkers for assessing the DMET-mediated DDI potential.
- Use of metabolite monitoring in DDI studies to improve the mechanistic interpretation of results.
- Mechanistic PK and PK/PD modeling of drug metabolites or parent metabolites.

Guest Editors

Dr. Mayur K. Ladumor

Dr. Xinning Yang

Dr. Eva Berglund

Prof. Dr. Rheem A. Totah

Deadline for manuscript submissions

closed (15 July 2024)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 8.1
Indexed in PubMed



mdpi.com/si/173755

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 8.1
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).